How fast does Beyfortus start working?
Beyfortus (nirsevimab-alb) is a passive immunization—an antibody given to help protect against RSV. Because it’s already an antibody, it begins providing protection immediately after it’s administered rather than requiring the body to build an immune response first.
When do people usually see the protection from a single dose?
Beyfortus is designed to cover the RSV season with a single dose. After the injection, protection is intended to be present early in the period following administration and to last through the risk window.
What factors could affect how quickly it works?
The main timing driver is when the dose is given relative to RSV exposure risk. Practical timing can also vary with:
- whether the patient receives the injection at the start of the RSV season versus later
- how soon the patient is exposed to RSV after dosing
- whether the patient is receiving Beyfortus for a preventive season plan versus after known exposure
How long does protection last after dosing?
Beyfortus is dosed to last for the length of the RSV risk period, which is why it is given as a single season dose for most use cases.
What if a child already has RSV symptoms?
Beyfortus is used to prevent RSV lower respiratory tract disease, not to treat established infection. If symptoms have already started, its benefit is different from prevention, and clinicians may use other management depending on severity.
Where the exact timing details usually come from
The precise “how many days” onset language depends on the study endpoints used (for example, time-to-protection against specific RSV outcomes). If you tell me the patient’s age/group (infant/child, or whether this is for season prevention vs another scenario) I can narrow the timing description to the relevant use case.